On April 29, Fosun Pharma (600196.SH; 02196.HK) announced its first quarter performance report for 2025. On the same day as the first quarter report was released, Fosun Pharma announced the adjustment of the division of labor of the board of directors.

After this adjustment, Wu Yifang will no longer serve as the executive director and chairman of Fosun Pharma, but will be the non-executive director of Fosun Pharma and will serve as the executive president of Fosun International; Wang Kexin will no longer serve as the co-chairman of Fosun Pharma, but will continue to serve as the executive director of Fosun Pharma and will serve as the executive president of Fosun International; Chen Yuqing will serve as the chairman and executive director of Fosun Pharma, Guan Xiaohui will serve as the co-chairman and executive director of Fosun Pharma, and CEO Wen Deyong will serve as the vice chairman and executive director of Fosun Pharma.

It is reported that in the future, Chen Yuqing will be fully responsible for Fosun Pharma's strategy, as well as important tasks such as organizational development, team training and talent reserve that match the strategic goals.

According to the first quarter financial report, Fosun Pharma achieved operating income of RMB 9.42 billion, net profit attributable to the parent company of RMB 765 million, and cash flow from operating activities of RMB 1.056 billion.

During the reporting period, Fosun Pharma continued to promote innovative transformation and the development and implementation of innovative products. The independently developed slulizumab injection (EU trade name: Hetronifly) was approved in the EU, and the licensed introduction of the world's first phosphate absorption inhibitor Ventil® (tenapanor hydrochloride tablets) was approved in China, and a number of innovative pipelines under development entered the key clinical/approval stage.

In addition, Fosun Pharma continued to strengthen global licensing cooperation and actively implement its internationalization strategy. In February 2025, the holding subsidiary Henlius granted Dr. Reddy's the exclusive commercialization rights for two dosage forms of its independently developed daratumumab biosimilar HLX15 in the United States and 42 European countries and regions, accelerating the entry of self-developed products into the European and American markets.

On April 28, Fosun Pharma just announced that it had reached a strategic cooperation with Fakeeh Care Group, a well-known comprehensive healthcare group in Saudi Arabia, to jointly promote the implementation of a number of leading therapies including biological drugs and CAR-T cell therapy in Saudi Arabia.

According to Fosun Pharma, this strategic cooperation is not limited to a technical alliance, but also represents the two companies' joint commitment to reshaping the medical and health industry landscape in Saudi Arabia and the entire Middle East, aiming to create a benchmark for the integration of advanced treatment technologies and remote diagnosis and treatment in the Gulf region, and help Saudi Arabia become a regional medical innovation center. Through this cooperation, Fakeeh Care Group and Fosun Pharma will further build a long-term strategic partnership, improve the quality of life of patients through innovation, and help Saudi Arabia achieve the goal of "Vision 2030" and become a leading global medical center.

Based on the confidence in its own sustainable development and recognition of its value, Fosun Pharma initiated and implemented a new round of A-share and H-share repurchases in 2025. In the first quarter, a total of 1,613,300 A-shares were repurchased for approximately RMB 39.9941 million; a total of 1,655,500 H-shares were repurchased for approximately HKD 22.9121 million.

https://finance.eastmoney.com/a/202504293393086489.html